Open AccessRisk factors associated with trastuzumab-induced cardiotoxicity in patients with human epidermal growth factor receptor 2-positive breast cancer
Author(s) -
Wesam Abdel-Razaq,
Mohammed Alzahrani,
Majed S. Al Yami,
Faisal Almugibl,
Mohammed Almotham,
Razan A. Alregaibah
Publication year - 2019
Publication title -
journal of pharmacy and bioallied sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.268
H-Index - 36
eISSN - 0976-4879
pISSN - 0975-7406
DOI - 10.4103/jpbs.jpbs_276_18
Subject(s) - trastuzumab , cardiotoxicity , medicine , breast cancer , oncology , taxane , cancer , medical record , chemotherapy
Although trastuzumab is a highly effective and selective targeted therapy for human epidermal growth factor receptor 2 (HER2)-positive breast cancer, the drug-induced cardiotoxicity may confine its usefulness in patients.